Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 62.6% in May

Aditxt, Inc. (NASDAQ:ADTX) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totaling 91,437 shares, a decline of 62.6% from the April 30th total of 244,575 shares. Based on an average daily trading volume, of 5,980,521 shares, the short-interest ratio is currently 0.0 days. Currently, 277.1% of the company’s shares are sold short.

Aditxt Stock Performance

Shares of ADTX opened at $0.12 on Friday. The firm has a market capitalization of $3,867.60, a PE ratio of 0.00 and a beta of 1.08. Aditxt has a 52-week low of $0.11 and a 52-week high of $53,451.08. The stock has a 50 day simple moving average of $10.77 and a 200 day simple moving average of $218.09.

Aditxt (NASDAQ:ADTX) last announced its earnings results on Tuesday, March 31st. The company reported $315,563.31 earnings per share for the quarter. Aditxt had a negative net margin of 360,152.50% and a negative return on equity of 374.60%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ADTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Aditxt in a report on Monday, April 20th. Wall Street Zen upgraded Aditxt to a “sell” rating in a research report on Saturday, May 23rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

About Aditxt

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.